Thursday, 20 January 2022

Covaxin is 77.8% Effective Against Covid as per Lancet Study

Covaxin is 77.8% Effective Against Covid as per Lancet Study

Covaxin, the covid vaccine developed by the government's medical research agency and Bharat Biotech, was found to have a 77.8 percent efficacy rate against COVID-19 in a long-awaited analysis published in Lancet. The study also found it to be 65.2 percent effective against the more vicious Delta variant of the coronavirus in its initial analysis. Still, it said further investigations are compulsory to confirm.

The Lancet said in a statement. Covaxin, which uses traditional, inactivated virus technology, "induces a strong antibody response" two weeks after two doses are given,

The medical journal said that no severe-vaccine-related deaths or adverse events were recorded during a randomized trial involving 24,419 participants aged 18-97 between November 2020 and May 2021 in India.

The study said.

"Efficacy against any severity of COVID-19 with start after 14 days the second vaccination was 77.8 per cent. Our initial analysis found an efficacy of 65.2 per cent against Delta variant, but further investigations are mandatory to confirm clinical efficacy against the variant and others,"

Covaxin is 77 8 Effective Against Covid as per Lancet Study 1unsplash image

Read More: Covaxin got Approval from WHO

The meantime study, which was funded by Bharat Biotech and the Indian Council of Medical Research and partly authored by officials at both bodies, is in line with the company's earlier efficacy and safety announcements and may help end the controversy surrounding the shot's early authorization in January in India and concerns in some countries.

The shot had yet to clear final-stage trials at the time, prompting widespread hesitancy in the early weeks of immunization drive. Since then, more than 100 million dosages of Covaxin have been deployed across India. Last week, the World Health Organization added the inoculation to its Covid vaccines authorized for emergency use.

The decision had been delayed as an advisory group sought additional clarifications from Bharat Biotech before running a final risk-benefit evaluation for the use of vaccines in the globe.

Strategic Advisory Group of Expert on Immunization of WHO's also recommended Covaxin's use in two doses, with intervals of four weeks, in age groups 18 plus. The recommendations are in line with the company's guidance.

The WHO's approval and a Lancet study could also cover the way for India to commit supply to the COVAX global vaccine sharing effort, which is co-led by the United Nations body and focuses on providing equitable access to shots for low and middle-income shots countries.

Follow Us

Popular Post

Delhi cold for a sixth consecutive day, IMD says relief likely soon

Delhi cold for a sixth consecutive day, IMD says relief like…

Farhan Sayyed Jan 18, 2022 Politics

Many Parts of Delhi recorded cold day conditions for the sixth consecutive day on Tuesday. Overcast skies and low clouds swing over the city even as I...